SCHEMBL7775484

SCHEMBL7775484

COc1ccc(/C=C/C(=O)Nc2ccccc2N)c(OCc2ccc(Br)cc2)c1CC=C(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 19/20 0.51
▸ HDAC4 P56524 10/20 0.51
▸ HDAC3 O15379 9/20 0.51
▸ HDAC7 Q8WUI4 9/20 0.51
▸ HDAC2 Q92769 9/20 0.51
▸ HDAC10 Q969S8 9/20 0.51
▸ HDAC11 Q96DB2 9/20 0.51
▸ HDAC8 Q9BY41 9/20 0.51
▸ HDAC6 Q9UBN7 9/20 0.51
▸ HDAC9 Q9UKV0 9/20 0.51
▸ HDAC5 Q9UQL6 9/20 0.51
▸ TUBB4A P04350 1/20 0.48
▸ TUBB P07437 1/20 0.48
▸ TUBA3C P0DPH7 1/20 0.48
▸ TUBA1B P68363 1/20 0.48
▸ TUBA4A P68366 1/20 0.48
▸ TUBB4B P68371 1/20 0.48
▸ TUBB3 Q13509 1/20 0.48
▸ TUBB2A Q13885 1/20 0.48
▸ TUBB8 Q3ZCM7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2338241 0.93 HDAC1 (0.51) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7776648 0.93 HDAC1 (0.51) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7776407 0.93 HDAC1 (0.51) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7776254 0.92 HDAC1 (0.51) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7776246 0.92 HDAC1 (0.51) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7775499 0.92 HDAC1 (0.48) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7781609 0.92 HDAC1 (0.49) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL8444854 0.92 HDAC1 (0.48) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL7779661 0.92 HDAC1 (0.48) HDAC1HDAC4HDAC3HDAC7HDAC2
SCHEMBL12300040 0.91 HDAC1 (0.42) HDAC1HDAC4HDAC3HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277387-B1 NEW USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY NATUREWISE BIOTECH & MEDICALS CORP (TW) 2016-10-19 — — EP disclosed
US-9427424-B2 Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2016-08-30 — — US disclosed
US-20140288166-A1 USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY NATUREWISE BIOTECH & MEDICALS CORP (TW) 2014-09-25 — — US disclosed
US-8784873-B2 Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2014-07-22 — — US disclosed
US-8318801-B2 Cinnamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2012-11-27 — — US disclosed
US-20110224294-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-09-15 — — US disclosed
US-7994357-B2 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-08-09 — — US disclosed
US-7994357-B2 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-08-09 — — US disclosed
US-20110020462-A1 NEW USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2011-01-27 — — US disclosed
US-20100256401-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2010-10-07 — — US disclosed
US-20100256401-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE NATUREWISE BIOTECH & MEDICALS CORPORATION (TW) 2010-10-07 — — US disclosed
EP-2236503-A1 Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase NatureWise Biotech & Medicals Corporation (TW) 2010-10-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020462-A1 NEW USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY BRPF3, BRD3, BRDT HDAC1 5/4885HDAC4 34/4885HDAC3 4/4885
US-20100256401-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE SMN1; SMN2, HDAC1, HDAC5 HDAC1 2/4885HDAC4 6/4885HDAC3 12/4885
US-20110224294-A1 CINAMIC COMPOUNDS AND DERIVATIVES THEREFROM FOR THE INHIBITION OF HISTONE DEACETYLASE SMN1; SMN2, HDAC1, HDAC5 HDAC1 2/4885HDAC4 6/4885HDAC3 12/4885
US-20140288166-A1 USE OF HISTONE DEACETYLASE INHIBITORS IN CHANGING MRJP3 PROTEIN IN ROYAL JELLY BRPF3, BRD3, BRDT HDAC1 5/4885HDAC4 35/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback